Bone-marrow analysis predicts breast-cancer recurrence

Molecular Medicine Today

Volumn 6, Issue 7, 2000, Pages 256-257

  Habeck, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EDRECOLOMAB; ESTROGEN RECEPTOR; KERATIN ANTIBODY;

BONE MARROW METASTASIS; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; NOTE; PREDICTION; PROGNOSIS;

EID: 0033919994     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01733-0     Document Type: Short Survey

References (2)

1. S. Braun Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer New Engl. J. Med. 342 2000 525 533
2. S. Braun Monoclonal antibody therapy with edrecolomab in breast cancer patients monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow Clin. Cancer Res. 5 1999 3999 4004